Abstract
Background: Hepatitis C virus (HCV) is a unique virus which interacts with cholesterol, iron and insulin metabolism. There is limited data on the effects of direct-acting antiviral agents (DAAs) on metabolic profiles. We aimed at evaluating the behavior of metabolic risk factors of chronically HCV-infected patients after sustained virologic response (SVR), comparing the outcomes with the new DAAs versus the old treatment regimen Peg-interferon ± ribavirin.
Methods: A total of 178 patients who achieved SVR and completed one year of follow-up were prospectively included in this study: group 1 with 105 patients treated with DAAs and group 2 with 73 patients treated with old regimens. Outcomes included lipid, glucose and iron metabolism variation after SVR.
Results: There was a significant increase in total cholesterol in both groups (group 1: p < .001, 95% CI: 0.41–0.78; group 2: p < .001, 95% CI: 0.24–0.69). Triglyceride levels significantly decreased (p = .015, 95% CI: −0.33–0.04) in group 1 and increased (p = .014, 95% CI: 0.07–0.59) in group 2. LDL levels increased in group 1 (p = .029, 95% CI: 0.05–0.88), but no significant variation was found in group 2. No significant variation in HDL, fast glucose and iron was seen in both groups. There was a significant increase of HOMA (p = .002, 95% CI: 0.17592–0.72317) only in group 2. Ferritin serum levels significantly decreased (p < .001, 95% CI:−138.3–74.4) in group 1 but no significant variation was found in group 2.
Conclusion: Patients who have achieved SVR may have increased risk of cardiovascular outcomes due to development of hyperlipidemia and insulin resistance.
Disclosure statement
No potential conflict of interest was reported by the authors.